KalVista Pharmaceuticals
KALV
About: KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Employees: 270
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,091% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $1.04M
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
61% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 18
8% more funds holding
Funds holding: 128 [Q1] → 138 (+10) [Q2]
0.99% less ownership
Funds ownership: 110.46% [Q1] → 109.47% (-0.99%) [Q2]
4% less capital invested
Capital invested by funds: $640M [Q1] → $615M (-$25.1M) [Q2]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 5 (-1) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Needham
Serge Belanger
|
$28
|
Buy
Reiterated
|
12 Sep 2025 |
|
JMP Securities
Jonathan Wolleben
|
$28
|
Market Outperform
Maintained
|
12 Sep 2025 |
|
HC Wainwright & Co.
Andrew Fein
|
$27
|
Buy
Reiterated
|
11 Jul 2025 |
|
Leerink Partners
Joseph Schwartz
|
$20
|
Outperform
Maintained
|
7 Jul 2025 |
Financial journalist opinion
Based on 8 articles about KALV published over the past 30 days
